Patients with early stage lung cancer live longer when they receive a lobectomy — the most common type of operation for the disease — rather than a less extensive operation or radiation treatment, according to a study published online in The Annals of Thoracic Surgery.

“Our data suggest that the more aggressively we treat early lung cancer, the better the outcome,” says lead author Alex Bryant, BS, of the School of Medicine at the University of California, San Diego. “This study is one of the best-powered and detailed analyses to date and suggests that lobectomy is still the preferred treatment of this disease for most patients.”

Using the Veterans Affairs Informatics and Computing Infrastructure (VINCI), Bryant, James D. Murphy, MD, and colleagues identified patients who were diagnosed with early stage non-small cell lung cancer (NSCLC) between 2006 and 2015, and who were treated with either surgery or radiation. In all, 4,069 patients were included: 73 percent (2,986) underwent lobectomy, 16 percent (634) received a sublobar resection, and 11 percent (449) received stereotactic body radiation therapy (SBRT). Lobectomy is the removal of an entire lobe of the lung; sublobar resection is a less extensive operation that includes wedge and segmental resections; SBRT delivers very high doses of radiation over a short period of time (typically 1-2 weeks), precisely targeting the tumor.

The researchers described VINCI as an “extremely rich source of health information” from which they were able to gather detailed data related to a large, nationwide group of veterans. The database includes patient-specific data related to preoperative pulmonary function, smoking history, and tumor staging. Factors such as these are often not available and have not been consistently addressed in previous studies, which sets this study apart, according to Bryant.

In their analyses, the researchers found that the 5-year incidence of cancer death was lowest in the lobectomy group at 23 percent, with the sublobar group at 32 percent, and SBRT patients at 45 percent. SBRT also was associated with a 45 percent increased risk of cancer death compared with lobectomy.

Surgery, though, was not without risks. The study showed that both surgical groups had higher immediate mortality compared to radiation due to operative risks. The 30-day mortality was 1.9 percent for lobectomy, 1.7 percent for sublobar resection, and 0.5 percent for SBRT. But as time went on and with longer follow-up, the surgery groups demonstrated superiority to SBRT, with long-term survival favoring surgery, especially lobectomy, over radiation. The 5-year overall survival rate for lobectomy patients was 70%, followed by the sublobar resection group at 56 percent, and SBRT at 44 percent.

“Our data suggest that the higher operative risks of surgery are more than offset by improved survival in the months and years after treatment, particularly for lobectomy,” says Bryant.

Increased Use of SBRT

The study also showed that the use of SBRT increased throughout the study period, accounting for 2 percent of all treatments in 2006 and 19 percent in 2015. Dr. Bryant explains that for patients who are too sick to tolerate a major operation like lobectomy, SBRT makes sense and has become an increasingly common option. Less extensive surgeries, such as sublobar resections, also remain a possibility, but there are ongoing concerns about a higher risk of tumor recurrences, he says. As a result, lobectomy remains the standard treatment for early lung cancer in patients who can tolerate a major surgical procedure.

“The public should be aware that lung cancer — even when caught at a very early stage — is a serious diagnosis and deserves aggressive treatment,” says Bryant.

Lung cancer is the leading cause of cancer death, with more people dying of lung cancer than of colon, breast, and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 80 percent to 85 percent of all lung cancer diagnoses, according to the American Cancer Society (ACS). ACS estimates that more than 222,500 Americans will be diagnosed with lung cancer this year, and more than 155,000 lung cancer patients will die. About 14 percent of all new cancers are lung cancers.